Resveratrol suppresses prostate cancer progression in transgenic mice

Carcinogenesis

Volumn 28, Issue 9, 2007, Pages 1946-1953

  Harper, Curt E ^a   Patel, Brijesh B ^a   Wang, Jun ^a   Arabshahi, Alireza ^a   Eltoum, Isam A ^b,c   Lamartiniere, Coral A ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ESTRADIOL; ESTROGEN RECEPTOR BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; RESVERATROL; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; TESTOSTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; TESTOSTERONE BLOOD LEVEL; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DIVISION; CROSSES, GENETIC; DISEASE PROGRESSION; FEMALE; HETEROZYGOTE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; STILBENES;

EID: 34848893955     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm144     Document Type: Article

References (56)

1. American Cancer Society (2006) Cancer Facts and Figures 2006. American Cancer Society, Atlanta, GA.
2. Sakr,W.A. et al. (1993) The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol., 150, 379-385.
3. Sakr,W.A. et al. (2000) Epidemiology and molecular biology of early prostatic neoplasia. Mol. Urol., 4, 109-113; discussion 115.
4. Ames,B.N. et al. (1998) The causes and prevention of cancer: The role of environment. Biotherapy, 11, 205-220.
5. Weisburger,J.H. (2002) Lifestyle, health and disease prevention: The underlying mechanisms. Eur. J. Cancer Prev., 11 (suppl. 2), S1-S17.
6. Wogan,G.N. et al. (2004) Environmental and chemical carcinogenesis. Semin. Cancer Biol., 14, 473-486.
7. Wolk,A. (2005) Diet, lifestyle and risk of prostate cancer. Acta Oncol., 44, 277-281.
8. Mentor-Marcel,R. et al. (2001) Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res., 61, 6777-6782.
9. Pace-Asciak,C.R. et al. (1995) The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: Implications for protection against coronary heart disease. Clin. Chim. Acta, 235, 207-219.
10. Kimura,Y. et al. (1985) Effects of stilbene derivatives on arachidonate metabolism in leukocytes. Biochim. Biophys. Acta, 837, 209-212.
11. Chanvitayapongs,S. et al. (1997) Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. Neuroreport, 8 1499-1502.
12. Jang,M. et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218-220.
13. Banerjee,S. et al. (2002) Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: Role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res., 62, 4945-4954.
14. Bhat,K.P. et al. (2001) Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res., 61, 7456-7463.
15. Whitsett,T. et al. (2006) Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J. Carcinog., 5 15.
16. Lin,H.Y. et al. (2002) Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J. Urol., 168, 748-755.
17. Kundu,J.K. et al. (2006) Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis, 27 1465-1474.
18. Manna,S.K. et al. (2000) Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol., 164, 6509-6519.
19. Jayatilake,G.S. et al. (1993) Kinase inhibitors from Polygonum cuspidatum. J. Nat. Prod., 56, 1805-1810.
20. Gao,S. et al. (2004) Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate, 59, 214-225.
21. Bowers,J.L. et al. (2000) Resveratrol acts as a mixed agonist/ antagonist for estrogen receptors alpha and beta. Endocrinology, 141, 3657-3667.
22. Vyas,S. et al. (2005) Resveratrol regulates insulin-like growth factor-II in breast cancer cells. Endocrinology, 146, 4224-4233.
23. Serrero,G. et al. (2001) Effect of resveratrol on the expression of autocrine growth modulators in human breast cancer cells. Antioxid. Redox Signal., 3, 969-979.
24. Aziz,M.H. et al. (2006) Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3′-kinase/Akt pathway and Bcl-2 family proteins. Mol. Cancer Ther., 5, 1335-1341.
25. Kim,Y.A. et al. (2003) Antiproliferative effect of resveratrol in human prostate carcinoma cells. J. Med. Food, 6, 273-280.
26. Morris,G.Z. et al. (2002) Resveratrol induces apoptosis in LNCaP cells and requires hydroxyl groups to decrease viability in LNCaP and DU 145 cells. Prostate, 52, 319-329.
27. Sgambato,A. et al. (2001) Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat. Res., 496, 171-180.
28. Greenberg,N.M. et al. (1995) Prostate cancer in a transgenic mouse. Proc. Natl Acad. Sci. USA, 92, 3439-3443.
29. Gupta,S. et al. (2004) Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res., 64, 3334-3343.
30. Gupta,S. et al. (2001) Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc. Natl Acad. Sci. USA, 98, 10350-10355.
31. Folkvord,J.M. et al. (1989) Optimization of immunohistochemical techniques to detect extracellular matrix proteins in fixed skin specimens. J. Histochem. Cytochem., 37, 105-113.
32. Wechter,W.J. et al. (2000) E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res., 60, 2203-2208.
33. Nyska,A. et al. (2003) Slowing tumorigenic progression in TRAMP mice and prostatic carcinoma cell lines using natural anti-oxidant from spinach, NAO - a comparative study of three anti-oxidants. Toxicol. Pathol., 31, 39-51.
34. Crowther,J.R. (2000) The ELISA guidebook. Methods Mol. Biol., 149, III-IV1-413.
35. Prins,G.S. (1989) Differential regulation of androgen receptors in the separate rat prostate lobes: Androgen independent expression in the lateral lobe. J. Steroid Biochem., 33, 319-326.
36. Gingrich,J.R. et al. (1999) Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis., 2, 70-75.
37. Le Corre,L. et al. (2004) Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines. Clin. Chim. Acta, 344, 115-121.
38. Horvath,L.G. et al. (2001) Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res., 61, 5331-5335.
39. Krege,J.H. et al. (1998) Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc. Natl Acad. Sci. USA, 95, 15677-15682.
40. Iwao,K. et al. (2000) Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers. Int. J. Cancer, 88, 733-736.
41. Ho,S.M. (2004) Estrogens and anti-estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates. J. Cell. Biochem., 91, 491-503.
42. Imamov,O. et al. (2004) Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. Proc. Natl Acad. Sci. USA, 101, 9375-9380.
43. Pak,T.R. et al. (2005) The androgen metabolite, 5alpha-androstane-3beta, 17beta-diol, is a potent modulator of estrogen receptor-beta1-mediated gene transcription in neuronal cells. Endocrinology, 146, 147-155.
44. Bonkhoff,H. et al. (1999) Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am. J. Pathol., 155 641-647.
45. Weihua,Z. et al. (2002) An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta;17beta-diol, and CYP7B1, regulates prostate growth. Proc. Natl Acad. Sci. USA, 99, 13589-13594.
46. Mueller,S.O. et al. (2004) Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol. Sci., 80, 14-25.
47. Yu,H. et al. (2000) Role of the insulin-like growth factor family in cancer development and progression. J. Natl Cancer Inst., 92 1472-1489.
48. Uzgare,A.R. et al. (2003) Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate, 55, 128-139.
49. Stewart,J.R. et al. (2004) Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition. Invest. New Drugs, 22, 107-117.
50. Putz,T. et al. (1999) Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res., 59, 227-233.
51. Nguyen,T.V. et al. (2005) Androgens, activate mitogen-activated protein kinase signaling: Role in neuroprotection. J. Neurochem., 94, 1639-1651.
52. Shappell,S.B. et al. (2004) Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the bar harbor meeting of the mouse models of human cancer consortium prostate pathology committee. Cancer Res., 64, 2270-2305.
53. Wikstrom,P. et al. (2005) Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy. Prostate, 62, 148-164.
54. Price,D. (1963) Comparative aspects of development and structure in the prostate. Natl Cancer Inst. Monogr., 12, 1-27.
55. Asensi,M. et al. (2002) Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med., 33, 387-398.
56. Yu,C. et al. (2002) Human, rat, and mouse metabolism of resveratrol. Pharm Res., 19, 1907-1914.